Briacell Therap (NASDAQ:BCTX) Trading Up 0.3% – Should You Buy?

Briacell Therap (NASDAQ:BCTX) shares were up 0.3% during trading on Monday . The company traded as high as $3.15 and last traded at $3.09. Approximately 91,575 shares were traded during trading, a decline of 70% from the average daily volume of 303,369 shares. The stock had previously closed at $3.08.

Analyst Ratings Changes

Several research firms have recently weighed in on BCTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Briacell Therap in a research report on Monday, April 20th. Wall Street Zen raised Briacell Therap from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Briacell Therap currently has an average rating of “Sell”.

Briacell Therap Price Performance

The firm has a market capitalization of $25.06 million, a price-to-earnings ratio of -0.12 and a beta of 1.21. The business’s fifty day simple moving average is $3.90 and its 200 day simple moving average is $5.42.

Briacell Therap (NASDAQ:BCTX) last released its quarterly earnings data on Tuesday, June 9th. The company reported ($0.99) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Flagship Harbor Advisors LLC bought a new position in Briacell Therap (NASDAQ:BCTX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned about 0.21% of Briacell Therap at the end of the most recent reporting period. 15.42% of the stock is currently owned by hedge funds and other institutional investors.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.